←
Caris Life Sciences7,416 posts
Caris Life Sciences avatar✓

Caris Life Sciences ✓

@carisls

Caris Life Sciences, the precision medicine pioneer, develops and delivers innovative solutions to revolutionize healthcare and improve the human condition.

◷ Joined March 2011▧ 2,489 Photos and videos
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 16

The MI Cancer Seek® platform provides comprehensive tissue-based molecular profiling through simultaneous DNA and RNA sequencing, while Caris Assure® offers blood-based analysis of circulating tumor-derived nucleic acids. Because tissue and liquid biopsy can provide complementary information, using both may help clinicians gain a broader molecular picture of a patient's cancer at diagnosis and during treatment. Learn more: ow.ly/FxO550ZYei1

Post attachment
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 16

Caris and collaborators presented two posters at the Association for Molecular Pathology (AMP) 2026 Annual Meeting demonstrating how Caris’ comprehensive Whole Transcriptome Sequencing (WTS) and clinico-genomic data are redefining fusion discovery by uncovering novel and rare gene fusions. “By applying WTS across a dataset of this scale, we can uncover new and rare fusions, better understand their clinical significance and generate insights that can help advance precision oncology,” said Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD. Learn more: ow.ly/I4ls5106CRy

Post attachment
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 13

Connect with Caris during the 31st Society for Neuro-Oncology (SNO) Annual Meeting and discover how comprehensive molecular profiling is advancing research and precision medicine in neuro-oncology. Visit booth 153 to learn more: ow.ly/1tjY5106xP9

Post attachment
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 12

Caris MI Clarity™ may offer insight into your breast cancer recurrence risk, helping you and your provider have a more informed conversation about what comes next. Ask your doctor if MI Clarity may be right for you. bit.ly/4n8Jb5f

Post attachment
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 11

November is Lung Cancer Awareness Month, a time to share stories of hope and progress. When Edwin Asturizaga was diagnosed with stage IV lung cancer, he nearly lost hope. But after turning to Caris for molecular profiling, things changed. Discover how advanced insights into his cancer helped transform his treatment plan. ow.ly/534Q51058v5

0:30
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 11

Caris Life Sciences announced that the first patients have been enrolled in a prospective, real-world observational study evaluating Caris ChromoSeq™, a Whole Genome Sequencing (WGS) assay designed to provide comprehensive genomic characterization of myeloid malignancies through a single integrated workflow. "Oncology has embraced comprehensive molecular profiling, yet patients with myeloid malignancies are often still evaluated through a fragmented testing process that requires multiple assays and workflows. Caris ChromoSeq was developed to challenge that paradigm,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. Learn more: ow.ly/r7ZB5105CR3

Post attachment
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 10

Caris is joining the molecular diagnostics community at the Association for Molecular Pathology (@AMPath) Annual Meeting and Expo. Visit Booth #600 to connect and learn how comprehensive DNA, RNA and protein analysis help advance precision oncology and personalized patient care. Learn more: ow.ly/HxaA5105xuG

Post attachment
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 10

Breadth and depth shouldn’t be a tradeoff —especially when patients need to know exactly what they’re fighting. Caris Assure® pairs the breadth of its 23,000+ gene Whole Exome Sequencing (WES) backbone with therapy-focused depth (up to 40,000x), helping clinicians identify actionable alterations from blood. Learn more: ow.ly/V9He51057U1

1:00
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 9

50 billion molecular markers. 1 million+ real patient cases. Caris Detect™ applies advanced AI trained on one of the largest oncological datasets of its kind to deliver early-stage cancer detection from a single blood draw. Order the test: CarisDetect.com

Post attachment
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 9

Caris Life Sciences announced the publication of a study in Clinical Cancer Research that used comprehensive molecular profiling to identify important biological differences among ESR1-mutated breast tumors and examine their association with time on treatment among patients receiving elacestrant. “This study highlights the complexity that exists within biomarkers that are often considered binary,” said Caris Chief Medical Officer George W. Sledge, Jr., MD, lead author of the study. Learn more: ow.ly/zobQ5104JC4

Post attachment
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 6

Join Caris at the @isliquidbiopsy ISLB 2026 and connect with the global liquid biopsy community. Visit Booth 5 to explore how comprehensive molecular profiling and liquid biopsy technologies are helping advance biomarker discovery, precision oncology and personalized treatment strategies. Learn more: ow.ly/kCgx5104ILv

Post attachment
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 6

Myeloid malignancies are genetically complex and often require multiple assays. Caris ChromoSeq brings the full genomic landscape into one high-coverage Whole Genome Sequencing (WGS) test, supporting clearer diagnosis and risk stratification in a single report. Learn more: bit.ly/4ufznZw

Post attachment
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 6

The stage at which cancer is diagnosed shapes outcomes. For certain cancers, five-year survival rate can exceed 90% at Stage I and fall below 10% at Stage IV. Caris Detect™ is a blood-based test designed to identify early-stage cancer signals, so patients can act sooner and increase there chances of survival. Order the test: CarisDetect.com

Post attachment
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 4

Caris Life Sciences released its third-quarter financial results today, which included revenue growth of 27% and raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29%. Learn more: ow.ly/sq8a5103S1v

Post attachmentPost attachmentPost attachmentPost attachment
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 4

When tumor heterogeneity raises questions, are you confident in the risk assessment? In a recent case of invasive lobular carcinoma, two distinct tumor regions showed discordant 21-gene assay scores. Caris MI Clarity™ evaluated two distinct tumor blocks and produced concordant early- and late-risk classifications, providing greater confidence that the reported risk reflected the patient's underlying disease risk. Learn more about how MI Clarity helped answer a challenging clinical question: ow.ly/QA3t50ZHLwL

0:21
Caris Life Sciences avatar
Caris Life Sciences@carisls·Nov 4

Caris is heading to Chicago for the LUGPA 2026 Annual Meeting! Visit booth 109 to connect with our team and explore how comprehensive molecular profiling can help inform personalized treatment decisions for patients with genitourinary cancers. We look forward to seeing you there!

Post attachment